Key facts
- Ruby Bio’s last known valuation is $24.0M (Jun 2025).
- It has raised $8.0M across 2 recorded rounds; the latest was Early Stage VC ($8.0M) in May 2025.
- Notable investors include Alumni Ventures, gener8tor, Joyance Partners, Dhuna Ventures, Fusion Fund — 12 tracked in total.
- Ruby Bio has filed 3 Form Ds with the SEC since 2022, most recently Jun 2025 ($8.0M sold to 22 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Ruby Bio
Funding rounds
2 roundsAbout Ruby Bio
Developer of a biomanufacturing platform intended for producing bio-based chemicals and ingredients from renewable feedstocks. The company's platform uses yeast-based fermentation to convert sugar and waste-derived inputs into biodegradable molecules, including biosurfactants, food emulsifiers, polyol sweeteners, biomonomers for polymers, and fermentation-derived oleochemicals, enabling manufacturers to obtain bio-based ingredients and chemical substitutes for industrial and consumer product applications.
- Sector
- Business Products and Services (B2B)
- HQ
- Oakland, CA, United States
- Founded
- 2022
- Employees
- 10
- Website
- rubybio.com/
- Ownership
- Privately Held (backing)
Ruby Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ruby Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ruby Bio in its N-PORT filings yet. We sweep new filings monthly.